iBio, Inc. (IBIO) News
Track canonical SquawkNews coverage tagged to IBIO, iBio, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
iBio Appoints Molly Carr Chief Medical Officer
iBio appoints new Chief Medical Officer
EQUITY | Aug 04, 2026, 11:00 AM UTC
L
iBio shares are trading higher after the company announced that a single dose of its IBIO-610 treatment lowered levels of metabolism regulat
iBio shares are trading higher after the company announced that a single dose of its IBIO-610 treatment lowered levels of metabolism regulator protein Activin E in primates for up to 8 weeks.
REGULATION | Jul 01, 2026, 02:38 PM UTC
L
iBio Announces New Preclinical Data From Obese Non-Human Primate Study Evaluating IBIO-610, Activin E Antibody Candidate
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove greater visceral and t
EQUITY | Jul 01, 2026, 11:08 AM UTC